NEOG

Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Neogen beats Where Food Comes From in revenue growth and recovery potential, but higher debt and integration risks complicate the food safety stock showdown.

Life sciences company Neogen (NASDAQ:NEOG) reported calendar Q3 2026 (fiscal Q1 2027) results beating Wall Street’s revenue expectations, with sales up 6.5% year on year to $222.8 million.

Neogen (NasdaqGS:NEOG) received a formal FDA warning letter tied to contamination issues in its HYCOAT(R) veterinary product.

Neogen’s third quarter results showed progress in both its Food and Animal Safety segments, but the market reaction was negative.

Neogen (NASDAQ:NEOG) outlined a multi-year strategy at its first Investor Day, emphasizing a shift from business stabilization toward accelerated growth, higher margins and stronger cash generation.

Shares of life sciences company Neogen (NASDAQ:NEOG) jumped 14.1% in the pre-market session after the company reported its third-quarter 2026 financial results and raised its full-year guidance for revenue and adjusted EBITDA.

Revenue grew 6.5% as Food Safety and Animal Safety segments both expanded.

Neogen shares fell 7.22% after an FDA warning concerning the recalled Neogen Vet product HYCOAT, which reporting tied to fungal contamination and at least 20 horse deaths. NEW YORK, Oct.

Key TakeawaysNeogen shares jumped 4% after fiscal first-quarter revenue of $222. 8 million beat the $208.

Moby summary of Neogen Corporation's Q1 2027 earnings call